Procarta was spun out from the John Innes Centre and Plant Biosciences Limited in March 2008.

The founders, Dr. Michael McArthur and Prof. Mervyn Bibb, discovered a novel way to control expression of genes in bacteria (Proc. Natl. Acad. Sci. USA 105: 1020) and developed the technology to treat drug-resistant bacteria.

Procarta raised seed funding in late 2008 and has achieved several key scientific milestones, including the development of lead compounds that are effective against two bacteria considered "Urgent Threats" by the US Center for Disease Control (Carbapenem-resistant Enterobacteriaceae and Clostridium difficile) and one "Serious Threat" (MRSA).